Intravitreal clindamycin as first-line therapy for toxoplasmic retinochoroiditis: A case series

Abstract

Purpose: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. Materials and Methods: Retrospective interventional case series. Results: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4–6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4–6 weeks. No recurrence or reactivation was noted until 2 years follow-up. Conclusion: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations.